G

GSK

Develops medicines, vaccines, and consumer health

Principal Process Pulse Engineer

Full-TimeUpdated Deadline 11/11/26
No salary listed
Senior
Bachelor's, Master's
Bengaluru, Karnataka, India
Hybrid
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • A bachelor's or master's degree in engineering, Computer Science, Information Technology, Automation, Data, Life Sciences, or a relevant technical discipline, or equivalent practical experience.
  • At least 7 years of hands-on technical engineering experience in complex enterprise or operational technology environments.
  • Experience implementing or supporting Process Analytical Technology platforms, such as Process Pulse, including configuration of data sources, models, dashboards, and data collectors.
  • Experience reviewing and approving specifications, design documents, configurations, test scripts, and technical validation evidence.
  • Experience leading complex troubleshooting and root-cause investigations across systems, interfaces, workflows, data, and infrastructure.
  • Experience coordinating internal engineers, site teams, vendors, and specialist partners through design, deployment, and stabilization activities.
  • Experience assessing technical risk and ensuring security, data integrity, resilience, compliance, and supportability requirements are met.
  • Experience with operational technology integrations and industrial protocols, such as OPC Unified Architecture or OPC Data Access between analyzers, controllers or programmable logic controllers, historians, and manufacturing systems.
  • Experience working in operational technology environments with segmented networks, firewalls, and operational technology security controls.
  • Experience supporting audits, inspections, or formal technical assurance activities.
Responsibilities
  • Implement Process Pulse technical designs and configurations, including servers, databases, data collectors, and dashboards, in line with approved operational technology architecture, segmentation, and product strategy.
  • Own technical quality for Process Pulse across assigned sites, including key specifications, design documentation, configuration records, and validation evidence.
  • Manage the lifecycle of Process Analytical Technology models, including creation, validation, deployment, monitoring, and retirement, across platforms such as Process Pulse and Unscrambler, ensuring models are version-controlled, traceable, and fit for process and quality use.
  • Own technical integration and data quality between modeling tools such as Unscrambler, Process Pulse, and execution or Quality Control systems so model outputs can be trusted for batch execution and investigations.
  • Design and configure Process Pulse data sources, Process Analytical Technology models, configurations, and access controls to support closed-loop control and real-time monitoring, including condition monitoring, root-cause analysis, and batch release.
  • Keep Process Pulse configurations, scripts, and infrastructure-as-code under version control, with automated deployment and upgrade checks and peer review of material changes, so operational technology integrations and platform changes remain traceable, repeatable, and supportable.
  • Lead the design and configuration of OPC-based and other operational technology integrations between Process Pulse, analyzers, control systems, and historians, in line with operational technology security standards and firewall patterns.
  • Monitor system behavior, including services, connectivity, licenses, and database performance; identify issues and lead troubleshooting and root-cause analysis across applications, integrations, and operational technology networks.
  • Plan and execute technical installations, upgrades, and patching for Process Pulse components; provide technical direction during releases and major incidents; and coordinate with infrastructure, operational technology, site teams, vendors, and operational technology security as needed to ensure stable and secure operations.
  • Work with Manufacturing Science and Technology, Manufacturing Execution System, and Data and Analytics teams to design or configure Process Pulse interfaces, workflows, recipes, and data models, and review related specifications and test scripts.
  • Coach site engineers, operational technology teams, and super users in Process Pulse patterns, including configurations, models, dashboards, OPC, and firewall behaviors, and contribute to training materials, runbooks, and knowledge articles.
  • Maintain and extend Process Pulse standards, reusable engineering assets, and deployment patterns aligned with operational technology design and security guidance; support technical assurance, audits, and inspections for Process Pulse deployments; and ensure non-conformances and exceptions are documented and mitigated.
  • Capture engineering lessons learned from Process Pulse projects and incidents and convert them into reusable standards, patterns, and training for other Process Analytical Technology and operational technology platforms, including other Process Analytical Technology platforms, Advanced Process Control, and Manufacturing Execution System integrations.
  • Use artificial intelligence-assisted development, agent-based workflows, and prompt templates for engineering, testing, documentation, and support, validating every artificial intelligence output for accuracy, security, Good Practice, data integrity, and maintainability before it is committed or released.
Desired Qualifications
  • Experience applying analytical and structured problem-solving approaches to technical issues.
  • Relevant technical, cloud, integration, automation, data, validation, cybersecurity, or engineering certifications.
  • Experience translating architecture and product direction into technical designs and implementation activities.
  • Experience producing technical documentation and maintaining specifications, designs, test evidence, and configuration records.
  • Experience with interfaces, workflows, data flows, environments, monitoring, and operational support.
  • Experience with security, quality, validation, data integrity, resilience, and change control requirements.
  • Experience collaborating across global business, site, engineering, architecture, product, service, and supplier teams.
  • Experience driving continuous improvement focused on standardization, reuse, automation, and knowledge sharing.
  • Experience providing technical leadership, constructively reviewing and challenging designs, and coaching engineers to transfer technical knowledge within and across teams.
  • Experience communicating technical risk, options, and recommendations to governance forums and senior stakeholders.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend

Company News

Yahoo Finance
Oct 28th, 2026
GSK Q3 sales rise 5% to $11.3B as specialty medicines drive growth, 2026 guidance reaffirmed

GSK reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, driven by specialty medicines. Core operating profit rose 5%, while core earnings per share rose 1%. The company reaffirmed its 2026 guidance, expecting sales and core operating profit in the upper half of their ranges. Higher interest costs after the $10.6 billion Nuvalent acquisition will hold core earnings per share growth in the lower half of its range. Specialty medicines grew 15%, led by Cabenuva, up 35%. Vaccines sales fell 2% on Shingrix destocking in China. Research and development spending rose 22%. GSK has started 18 phase III studies this year and expects four more. It declared a third-quarter dividend of 17 pence per share.

Yahoo Finance
Oct 28th, 2026
GSK shares slide as pipeline doubts and weak vaccine sales offset $11.3B sales beat

GSK shares fell about 4% on October 28 despite a third-quarter sales and profit beat, as investors focused on pipeline doubts and weak vaccine sales, including shingles shot Shingrix. The stock fell as much as 7.3% earlier in the day. Core profit was 54.6 pence per share on turnover of £8.89 billion, against expectations of 50.4 pence and £8.84 billion. Specialty medicines for HIV, respiratory conditions and cancer rose 15%, but sales of new asthma drug Exdensur and vaccines missed forecasts. Chief executive officer Luke Miels is running a £1.9 billion ($2.5 billion) cost-savings plan to fund drug development ahead of patent losses. Market forecasts for 2031 sales of £36.64 billion trail GSK's target of more than £40 billion. GSK kept its annual outlook and took a £328 million restructuring charge in the quarter.

Yahoo Finance
Oct 28th, 2026
FTSE 100 slips 0.3% ahead of budget as GSK falls 4.3% and Unilever drops 3.4% despite earnings beats

British stocks fell on Wednesday as investors awaited the budget and weighed results from GSK and Unilever. The FTSE 100 was down 0.30% at 08:18 GMT, extending Tuesday's fall. GSK was the top loser, down 4.3%, despite beating third-quarter expectations. Core earnings per share were 54.6 pence against a consensus of 50.4 pence, and revenue was £8.89 billion. Unilever fell 3.38% even after it raised its volume growth forecast to at least 3%. Finance Minister John Healey said he would scrap gas standing charges, which cost the typical household £108 a year. Standard Chartered raised its full-year targets after third-quarter pretax profit jumped 27% to $2.25 billion. Brent futures rose 1.4% to $110.91 a barrel.

Yahoo Finance
Oct 28th, 2026
GSK holds guidance as specialty drugs lift sales 5% to $11.3B, but $417M charge cuts profit 16%

GSK kept its 2026 guidance after specialty medicines drove another quarter of growth, though a £328 million restructuring charge cut its profit. Sales rose 5% at constant exchange rates to £8.9 billion. Core operating profit rose 5% to £3.1 billion, while total operating profit fell 16% to £2.1 billion. The charge relates to Accelerate Growth, a cost-cutting programme that targets £1.9 billion of annual savings by 2029 at a total cost of £2.4 billion. GSK plans to put the savings mainly into research and development. Specialty medicines grew 15% to £3.9 billion, while vaccines fell 2% to £2.6 billion. Net debt rose to £20.7 billion from £14.5 billion at the end of 2025, after the $10.8 billion Nuvalent takeover. Chief executive Luke Miels said GSK had "delivered another strong quarter.

Yahoo Finance
Oct 27th, 2026
GSK's oncology push: Jemperli FDA approval and strong ADC data at ESMO for $97.4B group

GSK presented late-stage oncology data at the ESMO Congress in October 2026 on three drugs: Jemperli, Mo-Rez and Ris-Rez. The £76.7 billion pharmaceuticals group is leaning on oncology as a key part of its mix. The US Food and Drug Administration (FDA) granted Jemperli accelerated approval for MSI-H/dMMR locally advanced rectal cancer. In the AZUR-1 trial, 71% of patients received dostarlimab alone, without additional treatment or progression in the assessment window. Mo-Rez showed a 62% confirmed response rate in platinum-resistant ovarian and endometrial cancers, with a median duration of 12.2 months. Ris-Rez delivered a 61% objective response rate in extensive stage small cell lung cancer. Investors should watch the phase III trials and AZUR-1 follow-up data.